Immune Network Ltd (fka IMMFF)

[Renee]

EDIT to blank.

[Renee]

IMMFF revoked:

http://www.sec.gov/litigation/admin/2013/34-68680.pdf

[Renee]

IMMFF: SEC Suspension:

http://www.sec.gov/litigation/suspensions/2012/34-68483.pdf

ORDER:

http://www.sec.gov/litigation/suspensions/2012/34-68483-o.pdf

ADMIN Proceeding:

http://www.sec.gov/litigation/admin/2012/34-68486.pdf

[thedog]

Does any one knows how many millions o/s share is there ?

[ragmuff]

Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial
Date : 12/30/2010 @ 4:41AM
Source : GlobeNewswire Inc.
Stock : Immune Network Ltd (IMMFF)
Quote : 0.05 0.0 (0.00%) @ 8:01AM


Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial

Immune Network Ltd (USOTC:IMMFF)
Intraday Stock Chart
Today : Thursday 30 December 2010

Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease (http://clinicaltrials.gov/ct2/show/NCT01222338).

The article entitled "Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB" appeared as e-publication ahead of print in the peer-reviewed, high-impact, Immunotherapy journal. The link to the abstract of paper is available at http://www.ncbi.nlm.nih.gov/pubmed/21182457.

The study, which was conducted by internationally recognized experts in the field of TB immunotherapy, Dr. Olga Arjanova and her team at Lisichansk TB Dispensary in the Eastern Ukraine, aimed to compare the impact of V5 immunotherapy to placebo among treatment refractory tuberculosis cases including re-treated TB, multi-drug resistant (MDR-TB) and TB with HIV co-infection.

The results of the newly published study support findings from the earlier published open label trial that appeared in October of this year in the Journal of Vaccines and Vaccination and provide further evidence of safety and clinical efficacy of V5.

The imm01 study indicated that V5 was safe, has not produced any adverse effects or reactivation of TB. Concurrent administration of V5 either with 1st- or 2nd-line TB drugs resulted in clearance of M. tuberculosis in sputum smears of 96.3% patients as opposed to 25% among placebo recipients. Sputum conversion occurred very quickly - only one month of treatment was needed. No difference was seen when "regular" easy-to-treat TB was compared to re-treated TB, MDR-TB or HIV-TB - the proportion of converted patients and time to conversion were identical. Another significant observation worthy of note is that the outcome appeared to be the same, regardless whether 1st line or 2nd line TB drugs were used.

One pill of Immunitor's V5 given once-per-day produced other statistically significant clinical benefits. V5 reversed TB-associated wasting: average weight gain was 3.4 kg in 100% of V5 patients vs. 1.07 kg in 67.9% of placebo patients. V5 also eliminated TB-associated fever in 100% vs. 39.3% of patients on placebo. Finally, V5 showed marked anti-inflammatory effect: erythrocyte sedimentation rate and leukocyte counts reverted back to within normal range in patients taking the Immunitor product. The relationship between anti-inflammatory property of V5 and bacterial clearance needs to be investigated further.

In addition to the anti-tuberculosis and positive clinical effects, Immunitor's V5 immunomodulator is also shown to reduce the hepatotoxicity induced by chemotherapy for TB, MDR-TB and XDR-TB. The serious adverse effects of TB drugs have important negative consequences on treatment options, not only causing direct damage to patient health but also decreasing the willingness of patients to comply with their TB treatment regimen.

Addition of V5 has been shown to counter the hepatotoxicity of TB drugs. For this reason the combination of V5 with ATT (anti-tuberculosis therapy) has an additional benefit of preventing or reversing drug-induced liver damage.

"Remarkable anti-TB activity was discovered accidentally during clinical trial in patients with chronic hepatitis C who also happened to have Mycobacterium tuberculosis and HIV co-infections," said Aldar Bourinbaiar, CEO of Immunitor company. "The goal of Immunitor is to investigate in depth the properties of V5 and, in so doing, eventually develop a vaccine that could do both, treat and prevent TB."

After AIDS, tuberculosis is the second most common cause of death from an infectious disease, with approximately 2 million people dying each year. Current treatments are not fully effective, particularly against multi-drug resistant TB (MDR-TB) and HIV-TB and strenuous treatment regimens lasting for up to 2 years are required. "Immunitor's approach has the potential to address current challenges – offering a drastically shorter, more efficacious and safer treatment solution. In addition, V5 is inexpensive; easy to administer; stable at tropical temperatures; and is made from readily available sources, which suits ideally developing countries where TB is rampant and patients are too poor to afford expensive 2nd line TB drugs," said Vichai Jirathitikal, co-founder and co-inventor of Immunitor oral vaccine platform. For additional information about Immunitor company, please visit www.immunitor.com.

Immune Network is in the final stages of its work toward meeting the conditions for a merger or other transaction. Additional corporate details and terms for the transaction with Immunitor will be announced shortly. A temporary website for Immune Network is at http://www.immune-network.com.

The Immune Network Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8008

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

CONTACT: Immune Network Ltd
[e-mail]

[hdsstocks]

100 billion annual world market!
http://www.otcmarkets.com/stock/IMMFF/news

[hdsstocks]

wheres the news!

[MONEYMADE]

,,,,,,I think today's news good for a few pence--MONEYMADE

[thedog]

first they have to make the SEC filing, release news and of course depends the millions of o/s shares.

[originunknown]

Thanks lifegear! Nothing seems to move this puppy, but who knows maybe one day.

[lifegear]

NEWS TODAY: Immune Network to Farm in on Australian Resource Exploration Properties and Soil Assay Biotechnology

Tuesday , February 13, 2007 04:11ET



VANCOUVER, BC -- (MARKET WIRE) -- 02/13/07 -- Immune Network Ltd (PINKSHEETS: IMMFF) announces an agreement for the acquisition of:

(a) A proprietary geochemical exploration biotechnology (OreSearch) for
the detection of mineral ore bodies through thick overburden (soil
layer).
(b) The exploration licenses to a number of properties (totaling
approximately 800 square kilometers) in Western Australia, where the
OreSearch technology has been employed to identify potential ore body
anomalies.
(c) All future benefit from completed exploratory, investigative and
analytical work and data on 60,000 sq km in the Meekatharra,
Mooloogool, Minilya-Winning and Byro regions (total completed
exploratory and analytical work at market replacement value is well
over USD 4 million).

The agreement with LocatOre Pty Limited, a Perth, Australia company associated with Immune Network Director, Mr. Peter Boonen, includes the following conditions:

1. Immune Network will issue 30,000,000 common shares to LocatOre and
further agrees to spend a minimum of USD 1,250,000 over three years
to "farm-into" the exploration tenements, and thereby acquire a 50%
ownership in the properties.
2. Immune Network has the option to obtain the remaining 50% of the
properties through the issuance of 85,000,000 shares in Immune Network
at anytime before 15 July 2010, subject to shareholder approval.
3. Subject to the completion of conditions 1 and 2, above, Immune Network
has the option to acquire a 100% interest in the OreSearch proprietary
biotechnology through the issuance of a further 25,000,000 shares in
Immune Network within one year of completing the above conditions,
subject to shareholder approval.

Immune Network has appointed New York-based Key Capital Corporation (PINKSHEETS: KCPC), a related party, to arrange the financing of Immune Network's farm-in and acquisition, and to assist and advise Immune Network in various aspects of business development. Under the agreement between Immune Network and Key Capital Corporation, Key Capital Corporation will receive 8,000,000 shares of Immune Network for services rendered over a 24-month period, as well has 16,000,000 warrants exercisable at $0.05 until the end of 2010.

In order to settle outstanding debt, Immune has issued and reserved 35,275,322 shares and, following the issue of the 30,000,000 farm-in and acquisition shares as announced today, Immune Network will have 86,193,100 shares outstanding and reserved for issuance. On a fully diluted basis, and subject to shareholder approval, on exercise of all warrants and options, 100% acquisition of the exploration tenements and the acquisition of the OreSearch technology a further 138,928,965 shares would be issued resulting in the Company having 225,122,065 shares issued and outstanding.

The unique "OreSearch" soil assay biotechnology has been able to identify and/or discover buried or "blind" ore bodies. These ore bodies often occur at depth and have a negligible surface expression in terms of geochemical signature. In addition these ore bodies are often also geophysically blind, thus increasing the difficulty of their discovery.

The OreSearch technology, through research funding agreements with the School of Applied Chemistry at Curtin University in Perth, Western Australia, has been successfully proven through it application in Curtin University research projects with established resource industry companies. It has identified and/or located significant resources for a number of major mining companies including: Normandy, RTZ, Homestake, Argyle, Minorco (Anglo American), Delta Gold, AurionGold, Ashton Mining, Rio Tinto Exploration, CRAE, Tulloch Resources, Geographe Resources and Bann Geological Services Pty Ltd.

About Key Capital Corporation:

Key Capital Corporation is a boutique investment banking group that identifies undervalued assets globally. Key Capital can assist its portfolio companies with creative structured solutions that address often complex financing needs and, where applicable, subsequent public listing. Key Capital through its global relationship network within the equities, finance, accounting and legal business sectors is able to arrange diverse corporate services, including public offerings, mergers and acquisitions, financial structuring, and commercial advice.

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projections and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

--------------------------------------------------------------------------------For further information please contact:
Ed Levinson
1-650-241-1888
Email Contact

Source: Immune Network Ltd

[originunknown]

19M or less ... only problem is no interest right now .... that may come later.

[lifegear]

I think the float is really tiny

[originunknown]

Either they don't want to spend the money on updates, or are just not ready to move forward yet.

Could be a long haul for this puppy that had so much potential initially.

[lifegear]

but the acquisition was just Jan 2006...they don't update their website for some reason and I still have to find that Dr. Nature Health Products Inc

[originunknown]

Virtually no trading volume to speak of ...

3 Months Close Prices
Date Ex : Sym Open High Low Close Chg Vol #Tr Bid Ask
2006-09-08 Q : IMMFF
2006-09-07 Q : IMMFF 0.015
2006-09-06 Q : IMMFF
2006-09-05 Q : IMMFF 0.015
2006-09-01 Q : IMMFF 0.03 0.03 0.03 0.03 0.015 10,450 2
2006-08-31 Q : IMMFF 0.03 0.03 0.015 0.015 -0.015 2,850 5
2006-08-30 Q : IMMFF 0.015 0.03 0.015 0.03 0.015 3,500 3
2006-08-29 Q : IMMFF
2006-08-28 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 200 1
2006-08-25 Q : IMMFF
2006-08-24 Q : IMMFF
2006-08-23 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 2,000 1
2006-08-22 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 1,100 2
2006-08-21 Q : IMMFF
2006-08-18 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 300 1
2006-08-17 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 500 1
2006-08-16 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 270 1
2006-08-15 Q : IMMFF
2006-08-14 Q : IMMFF
2006-08-11 Q : IMMFF
2006-08-10 Q : IMMFF
2006-08-09 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 5,000 1
2006-08-08 Q : IMMFF
2006-08-07 Q : IMMFF
2006-08-04 Q : IMMFF 0.015 0.03
2006-08-03 Q : IMMFF 0.01 0.03
2006-08-02 Q : IMMFF
2006-08-01 Q : IMMFF 0.015 0.045
2006-07-31 Q : IMMFF
2006-07-28 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 1,250 1
2006-07-27 Q : IMMFF 0.015 0.045
2006-07-26 Q : IMMFF
2006-07-25 Q : IMMFF 0.015 0.015 0.015 0.015 -0.015 500 1
2006-07-24 Q : IMMFF 0.03 0.03 0.03 0.03 0.015 500 1
2006-07-21 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 600 2
2006-07-20 Q : IMMFF
2006-07-19 Q : IMMFF
2006-07-18 Q : IMMFF 0.015
2006-07-17 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 100 1
2006-07-14 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 2,000 1
2006-07-13 Q : IMMFF
2006-07-12 Q : IMMFF
2006-07-11 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 1,000 2
2006-07-10 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 100 1
2006-07-07 Q : IMMFF
2006-07-06 Q : IMMFF 0.03 0.03 0.015 0.015 0.00 8,530 3 0.015
2006-07-05 Q : IMMFF 0.033 0.033 0.015 0.015 0.00 10,550 4
2006-07-03 Q : IMMFF
2006-06-30 Q : IMMFF
2006-06-29 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 450 1
2006-06-28 Q : IMMFF
2006-06-27 Q : IMMFF 0.033 0.033 0.015 0.015 0.00 8,800 3
2006-06-26 Q : IMMFF
2006-06-23 Q : IMMFF 0.015
2006-06-22 Q : IMMFF
2006-06-21 Q : IMMFF
2006-06-20 Q : IMMFF
2006-06-19 Q : IMMFF
2006-06-16 Q : IMMFF
2006-06-15 Q : IMMFF
2006-06-14 Q : IMMFF 0.015
2006-06-13 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 350 1 0.015
2006-06-12 Q : IMMFF 0.015 0.015 0.015 0.015 0.00 150 1 0.015

[originunknown]

Website news goes back to 2003 .. hope this puppy wakes up some day.

[lifegear]

Immune Network Ltd. is a biotechnology company focused on the development of new drugs to treat major diseases predominantly involving the body's immune system. The Company's projects include Alzheimer Project AD2 and AIDS Project 1F7 and hNM01, including Hepatitis C Monoclonal Antibodies. During the year ended December 31, 2001, Immune Network suspended various projects due, in part, to fiscal constraints and for commercial reasons, although it has retained an interest in some of the projects by way of royalties in future revenues, if any. Suspended projects include Asthma Project BP1, Eczema Project BP1249, Cancer Project Viraplex, and Herpes Cold Sore Project Zorex.

[lifegear]

I found it...85% acquisition

Immune Network to Tackle Diabetes
Market Wire, January, 2006
Immune Network Ltd. (OTC: IMMFF) advises that it has acquired an 85% interest in B.C.-based Dr Nature Health Products Inc. -- which has a breakthrough natural health product, DRN 11, that is proven clinically beneficial in the management of diabetes -- in exchange for 7.5 million Immune Network shares.

Immune will now commence marketing DRN 11, the flagship product developed by Dr Nature over the past eight years. Completed regulatory filing for DRN 11 in Canada allows the Company to commence sales immediately. Sales into the U.S. and other markets will also be pursued.

Pre-clinical studies have demonstrated that DRN 11 sensitizes the body's response to its own insulin making it work more efficiently (by increasing insulin binding and internalization). As a result of better utilization of insulin, muscle cell glucose uptake is increased. The significant clinical benefits against all diabetes symptoms and complications have been demonstrated through three DRN 11 clinical studies.

DRN 11 is an excellent supplement compound that can be used alongside prescription medications such as the US$800 million drug Metformin. In the DRN 11 clinical studies, reductions in the range of 15-20% in blood sugar levels have complemented a noted quality of life benefit with no side effects and an overall improvement in the well being and general health of the study participants.

Diabetes is the third leading cause of death in the United States with an economic cost of over $100 billion per year and affecting 18.2 million people with an estimated 15 million not yet diagnosed.

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

For further information contact: Dr. Allen Bain 1-650-241-1888 Email Contact

[lifegear]

maybe it's time to add some more....I thought I saw IMMFF acquire a nutritional supplement company earlier this year but I can't find it anymore now that Knobias got rid of their free service

[originunknown]

sure hope so .. maybe a little ACTC trick might help!
'

[lifegear]

me too...it's about time something happens to this dormant drug company

[originunknown]

I have owned some of this for years and almost forget I have it at times. First listed in Canada they switched to OTCBB which has puzzled me. The CEO thought he would have better access to American markets but the opposite result was obtained.

I see the price has improved a little.